






A Tale of 3 Pathways
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York, USAA renewed interest in the role of complement in the pathogenesis of glomerular diseases has improved
our understanding of their basic, underlying physiology. All 3 complement pathways—classical, lectin,
and alternative—have been implicated in glomerular lesions both rare (e.g., dense deposit disease) and
common (e.g., IgA nephropathy). Here we review the basic function of these pathways and highlight, with
a disease-speciﬁc focus, how activation can lead to glomerular injury. We end by exploring the promise of
complement-targeted therapies as disease-speciﬁc interventions for glomerular diseases.
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CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).I n clinical practice, a nephrologist evaluating a patientwith a glomerular disease always begins with a sim-
ple, dichotomous classiﬁcation scheme. The glomerular
disease is considered either “primary” (intrinsic to the
kidney) or “secondary” (a renal manifestation of a sys-
temic disease that can also affect other organ systems).
For example, in approximately 25% of patients whose
kidney biopsies show the lesion of membranous ne-
phropathy, a systemic disease process such as lupus,
hepatitis B, or cancer will be identiﬁed as the underly-
ing etiology of the lesion. Traditionally, the primary
glomerular lesions have also been called idiopathic,
often with the suggestion of an underlying, ill-deﬁned
autoimmune process. In recent years, advances in our
understanding of the pathophysiology behind many
of the glomerular diseases have gradually chipped
away at this “idiopathic” nomenclature. One area of
major advances has been through a heightened appreci-
ation of the role of complement in glomerular injury.
This complement-oriented approach has allowed
nephrologists to come increasingly close to answering
the question most commonly posed by patients—Why
did this happen?—and has provided a guide to
prognosis and treatment of a number of glomerular
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published online 1 July 2016Overview of Complement Pathways
The complement system is divided into 3 initiating
pathways—the classical, lectin, and alternative path-
ways (Figure 1). Proper functioning of each pathway is
required for coordinated activity of innate and ac-
quired immunity.1 The 3 initiating pathways all
converge at C3 to generate an enzyme complex known
as C3 convertase that cleaves C3 into C3a and C3b. The
association of C3b with C3 convertase results in gen-
eration of C5 convertase, which cleaves C5 into C5a and
C5b. This cleavage triggers the terminal complement
cascade, the assembly of the membrane attack complex
(MAC), which is also known as C5b-9, and subsequent
cell lysis or sublytic cellular injury.
Although all 3 pathways converge at a similar level
and therefore have similar downstream targets, the
pathways are distinct in their points of origin. The
classical complement pathway, which plays a major
role in humoral immunity, is “triggered” into action by
either IgG or IgM antibodies bound to antigen. This
immune complex formation of antigen and antibody
exposes a binding site on the Ig for the ﬁrst component
of the classical pathway, C1. The lectin pathway is
initiated by the binding of mannose-binding lectin to
the polysaccharide surface of pathogenic bacteria. This
binding results in the formation of a trimolecular
complex with 2 serine proteases and subsequent
cleavage of C4 and C2, the next complement proteins in
the cascade. In this pathway, C4b and C3b can bind to
antigen-associated Igs as well as to microbial surfaces.
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Figure 1. An overview of the complement cascade. The classical, mannose-binding lectin and alternative complement pathways converge at
C3 to generate an enzyme complex known as C3 convertase that cleaves C3 into C3a and C3b. However, the pathways are distinct in their points
of origin. The classical complement pathway is activated by either IgG (predominantly IgG1 and IgG3) or IgM antibodies bound to antigen; this
immune complex exposes a binding site on the Ig for the first component of the classical pathway, C1, to form a C1 complex that cleaves C2 and
C4. The lectin pathway is initiated by the binding of mannose-binding lectin (MBL) to the polysaccharide surface of pathogenic bacteria. This
binding results in the formation of a trimolecular complex with mannose-binding lectin-associated serine proteases (MASPs) and subsequent
cleavage of C2 and C4. IgG4 and IgA1 autoantibodies can also bind MBL and activate the lectin complement pathway. The alternative pathway
begins at the level of C3 and is constitutively active via spontaneous hydrolysis of C3 to C3b, which binds factor B to yield the C3 convertase
(C3bBb) of this pathway. Hence, activation of this complement pathway is generally considered antibody independent. MAC, membrane attack
complex; MCP, membrane cofactor protein.
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the alternative pathway is also constitutively active
via spontaneous hydrolysis of C3 to C3b, which
binds factor B to yield the C3 convertase (C3bBb) of this
pathway.
This distinction, between the constitutively active
alternative pathway versus the triggered classical and
lectin pathways, is manifest on immunoﬂuorescence
(IF) studies, which are performed routinely on all
medical kidney biopsy specimens (Table 1). Specif-
ically, the presence of Ig staining (IgG, IgM, and/or
IgA) alongside complement on IF microscopy implies
that immune complexes of antigen-antibody have
triggered consumption of the classical and/or lectinKidney International Reports (2016) 1, 148–155pathway proteins (Figure 1), whereas the presence
of C3 staining alone without Ig suggests that the
glomerular lesion is mediated by complement alone in
an antibody-independent fashion, implicating the
alternative complement pathway.2 For the treating
nephrologist, these IF patterns in turn focus the work-
up and treatment of the glomerular disease on (i) the
trigger in classical or lectin pathway–mediated injuries,
with attention toward infectious, autoimmune, malig-
nant, or drug-induced etiologies, versus (ii) the “dys-
regulation” of the constitutively active alternative
pathway in C3-mediated lesions, with attention toward
genetic mutations or autoantibodies targeted at com-
ponents of the alternative pathway.3149





Lupus nephritis þ þ þ
C3 glomerulopathy – þ –
Membranous nephropathy þ þ –
IF, immunoﬂuorescence.
IF staining can highlight which complement pathway is involved in disease pathogen-
esis. In lupus nephritis, IF staining should be positive for IgG, C3, and C1q, indicating a
role for IgG activation of the classical complement pathway. The classic IF pattern of C3
glomerulopathies is isolated staining of C3 with negative Ig and C1q staining, implicating
alternative pathway activation. In primary membranous nephropathy, the presence of
IgG and C3 staining on IF with absent C1q staining suggests a pathogenic role of the
lectin pathway.
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Glomerulonephritis
Systemic lupus erythematosus is a chronic autoimmune
disease that can affect multiple organs, including the
skin, joints, brain, peripheral nervous system, heart,
gastrointestinal tract, and kidneys. Renal involvement
in systemic lupus erythematosus, generally termed
lupus nephritis (LN), is a major contributor to disease
morbidity and mortality. Up to 50% of patients with
systemic lupus erythematosus will have clinically
evident kidney disease at presentation; during follow-
up, renal involvement occurs in up to 75% of pa-
tients, with an even greater representation among
children and young adults. In addition to nonspeciﬁc
laboratory ﬁndings of changes in serum creatinine level
and presence of proteinuria and/or hematuria, mea-
surement of serum complement components (C3, C4)
are an important screening test for LN if kidney
involvement is suspected. Both C3 and C4 are often low
when disease is systemically active, as is usually the
case with any severe, proliferative form of LN.4
The classic pattern of LN is an immune complex–
mediated glomerulonephritis (GN) with a varied pa-
thology that includes 6 distinct classes of disease.5 The
glomerular deposits in LN stain dominantly on IF mi-
croscopy for IgG with codeposits of IgA, IgM, C3, and
C1q (Table 1) in a so-called full house pattern. The role
of the classical complement pathway in mediating
glomerular injury in LN is critical in understanding
these and other representative biopsy ﬁndings in LN.
The immune deposits in LN are primarily immune
complexes of anti–double-stranded DNA antibodies
directed against nucleosomal antigens. A smaller frac-
tion of autoantibodies can also bind directly to chro-
matin in the glomerular basement membrane (GBM) and
mesangium.6,7 These immune complexes, when depos-
ited in the mesangium and subendothelial space, are
proximal to the GBM and in communication with the
systemic circulation. Subsequent activation of the
classical complement pathway, triggered by the
DNA–anti-DNA antibody complex formation, generates150the potent chemoattractants C3a and C5a, which elicit an
inﬂux of neutrophils and mononuclear cells. The
pattern on light microscopy (LM) is a proliferative GN
that can be mesangial (class II), focal endocapillary (class
III), or diffuse endocapillary (class IV). Immune complex
deposits in the subepithelial space can also activate
complement but only locally; the chemoattractants (C3a
and C5a) are separated from the circulation by the GBM,
and hence no inﬂux of inﬂammatory cells occurs into
this space. The injury in this class V LN (so-called
membranous LN) is limited to the glomerular epithelial
cells, the primary clinical manifestation is proteinuria,
and the histologic pattern on LM is similar to that of
primary membranous nephropathy.
Primary Membranous Nephropathy and the
Lectin Complement Pathway
Our understanding of the pathophysiology behind the
membranous nephropathy (MN) lesion has made a
seismic leap in the last decade with the identiﬁcation of
target antigens and their associated autoantibodies,
which are responsible for the majority of primary MN
cases. In 2009, Beck et al.8 reported that the M-type
phospholipase A2 receptor (PLA2R) was the speciﬁc
podocyte antigen responsible for eliciting immune
complex formation with circulating autoantibodies.
Anti-PLA2R antibodies were detected in approximately
75% of idiopathic MN cases and rarely found in sec-
ondary forms of MN (e.g., lupus-, hepatitis-, and
tumor-associated MN).8 Additional alternative podo-
cyte autoantigens—–mitochondrial superoxide dis-
mutase 2, aldose reductase, alpha-enolase, neutral
endopeptidase,9 and, most recently, thrombospondin
type-1 domain-containing 7A10—have been reported in
patients with primary MN, potentially ﬁlling in the
missing gaps in PLA2R antibody–negative disease.
These breakthroughs have established MN as a disease
of autoantibodies and potentially made the term idio-
pathic defunct.
Membranous nephropathy occurs when circulating
antibodies permeate the GBM and, in the subepithelial
space, form immune complexes with epitopes on
podocyte membranes. This in situ antigen-antibody
interaction leads to activation of complement; the
ensuing formation of the MAC inﬂicts sublytic damage
on the podocyte (leading to foot process effacement)
and induces secretion, from the damaged podocyte, of
additional extracellular material that further expands
the GBM. The important role of complement in
glomerular injury in MN is supported by the consistent
ﬁnding of C3 and C5b-9 in the subepithelial deposits
that, along with dominant granular staining for IgG,
deﬁne the disease. The dominance of IgG4 in primary
MN mediated by anti-PLA2R, as compared with theKidney International Reports (2016) 1, 148–155
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(e.g., in the setting of malignancy, in which IgG1 is
more commonly found), raises questions about which
complement pathway is most prominently involved in
the pathogenesis of the MN lesion.
IgG4 is incapable of binding C1q and therefore is
unable to activate complement via the classical
pathway. Indeed, positive C1q staining in membranous
nephropathy, a signal of classical complement pathway
activation, often suggests a secondary form of the
lesion, such as lupus MN. In contrast, IF staining for C3
and C4d, a breakdown product of C4b, in the absence
of C1q is characteristic of primary MN (see Table 1),
and formation of the MAC at the site of glomerular
injury is required for the development of proteinuria.11
The most reasonable explanation for these ﬁndings is
that the C3, C4d, and the MAC detected in these biopsy
specimens result largely from activation of the lectin
complement pathway.12 Anti-PLA2R IgG4 autoanti-
bodies can bind mannose-binding lectin and activate
the lectin complement pathway. Presumably, the
IgG4 autoantibodies directed at other, less common
autoantigens associated with primary MN (e.g., anti–
thrombospondin type-1 domain-containing 7A anti-
bodies) can also trigger activation of the lectin
pathway. Evidence of the lectin pathway’s role in MN
has surfaced in biopsy specimens from affected chil-
dren that show mannose-binding lectin codepositing
with IgG4.13
Alternative Complement Pathway–Mediated
GN: The C3 Glomerulopathies
The alternative complement pathway is constitutively
active at a low level. The term tickover has been used to
describe this basal physiologic activation of the alter-
native pathway by spontaneous hydrolysis of C3 and the
production of C3b, which binds factor B to yield a ﬂuid
phase C3 convertase (C3bBb).14 This alternative path-
way C3 convertase, though, is under tight control by
soluble or membrane-bound regulating proteins,
including complement factor H, complement factor I,
and membrane cofactor protein (see Figure 1). Thus, a
genetic or acquired (i.e., via autoantibodies or mono-
clonal gammopathies that interfere with complement
regulatory proteins) defect in either the activation or
regulation of the C3 convertase could lead to a trans-
formation from low-grade physiologic activity (tickover)
to unrestrained, hyperactivity (diseases of complement
dysregulation). This loss of alternative pathway control
can result in GN that on IF stains only (or dominantly) for
C3, with complement proteins (and not immune com-
plexes) mediating the glomerular injury.
The reclassiﬁcation of idiopathic membranoprolifer-
ative GN (MPGN) highlights how nephrologists andKidney International Reports (2016) 1, 148–155pathologists have incorporated the role of complement
into their approach to disease.15,16 Traditionally,
MPGN was categorized according to ultrastructural
ﬁndings on electron microscopy. Subendothelial and
mesangial deposits predominated in MPGN type I,
highly electron dense intramembranous and mesangial
deposits were the hallmark of type II, and in type III
MPGN, deposits could be subendothelial and sub-
epithelial (Burkholder subtype) or produce complex
intramembranous, subendothelial, and subepithelial
formations with fraying of the lamina densa (Strife and
Anders subtype). A major drawback of the mem-
branoproliferative GN–based classiﬁcation scheme was
that it was based on histopathologic patterns and not
on pathophysiology of disease.17 For example, many
patients with intramembranous dense deposits, char-
acteristic of MPGN type II, lacked an MPGN pattern
altogether on LM, which led to use of the more accurate
and inclusive term dense deposit disease (DDD). In
addition, some cases of MPGN type I and type III had
only C3 immune deposits distinct from the more com-
mon variants of type I and type III MPGN that contain
Ig. These cases resembled DDD and were rebranded as
C3 GN. Currently, the term C3 glomerulopathy has been
proposed as an umbrella classiﬁcation for any GN
(including non-MPGN LM patterns) with isolated or
dominant C3 staining. The term encompasses both DDD
and C3 GN and signals an etiology rooted in dysregu-
lation of the alternative complement pathway.18
The C3 glomerulopathies overlap with atypical
hemolytic uremic syndrome (aHUS [also termed
complement-mediated thrombotic microangiopathy19]) in
genetic abnormalities (e.g., mutations in factor H, fac-
tor I, membrane cofactor protein, C3, and factor B) and
autoantibodies (e.g., anti–factor H autoantibodies)
reported in these diseases.20–23 Yet, aHUS differs from
the C3 glomerulopathies where the alternative pathway
dysregulation occurs. The alternative pathway consists
of a network of complement proteins in either the ﬂuid
phase as soluble plasma proteins or in the solid phase as
cell membrane proteins. The underlying defect in most
instances of the C3 glomerulopathies is felt to be
excessive activation of the alternative complement
pathway in the ﬂuid phase.3,24,25 In contrast, the
endothelial damage that is the hallmark of aHUS is due
to dysregulation at the level of the cell membrane or in
the solid phase.14
Overlaps: Glomerular Lesions Mediated by
More Than 1 Complement Pathway
It may turn out to be overly simplistic to think of only
1 complement pathway for a speciﬁc glomerular dis-
ease. For example, a French cohort study comparing
patients with immune complex-mediated MPGN type I151
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C3 GN (i.e., C3 alone on IF) found virtually equal rates
of genetic mutations and autoantibodies targeted at
alternative complement pathway regulatory proteins.
This suggests that a subgroup of patients with immune
complex–mediated lesions, and subsequent classical
pathway–mediated injury, also have an underlying
defect in alternative pathway control, a defect that in
turn may have made these patients more susceptible to
formation of the antigen-antibody interactions that
triggered their classical pathways and initiated subse-
quent disease.26 With regard to MN, a recent report
from Bally et al. describes 5 patients with primary,
PLA2R-associated MN and genotypes associated with
mannose-binding lectin deﬁciency, suggesting that, in
these patients, complement activity was more likely in
the alternative pathway rather than in the lectin
pathway.27
IgA nephropathy, the most common form of primary
GN worldwide, appears to be a disease mediated by
both the mannose-binding lectin and alternative com-
plement pathways. A multihit pathogenesis model of
IgA nephropathy has emerged: abnormal polymeric
IgA1 with deﬁcient O-linked glycosylation at the hinge
region (galactose-deﬁcient IgA1) forms immune com-
plexes with IgG antibodies directed at the abnormal
hinge region (antiglycan antibodies), and these immune
complexes are then deposited in the mesangium.28 On
LM, mesangial proliferation and matrix expansion are
the typical ﬁndings of IgA nephropathy, and the
diagnosis is established by dominant IgA staining on IF
microscopy. The IF microscopy can also show codom-
inant or subdominant staining of IgG, C3, C4d, and
C5b-9 that colocalize with IgA. C1q staining, however,
is generally absent, suggesting no role of the classical
complement pathway in the pathogenesis of disease.
Instead, these IF ﬁndings suggest a potentially impor-
tant contribution from both the alternative and lectin
complement pathways.29 IgA1 can activate both path-
ways in vitro, and pathway components are present in
the mesangial deposits, including properdin and factor
H of the alternative pathway and mannose-binding
lectin, mannose-binding lectin–associated serine pro-
teases 1 and 2, and C4d of the lectin pathway. Indeed,
intensity of C3 staining and deposition of mannose-
binding lectin, respectively, have both been shown
in small studies to correlate with severity of IgA ne-
phropathy.30–32
Postinfectious GN—a diffuse, exudative, and pro-
liferative lesion that is mainly seen in response to
bacterial infections (most commonly streptococcal or
staphylococcal species)—classically follows an acute
self-limited infection. The latency period from infection
to GN, presumably the time required for antibodies152directed at the offending bacteria to form immune
complexes with intrinsic tissue that is in turn deposited
in the glomerulus, is approximately 2 weeks. This
rationale for the development of postinfectious GN
implicates activation of the classical complement
pathway by circulating immune complexes, which is
supported by staining on IF for both C3 and IgG.
However, staining of C3 is usually of equal or greater
intensity than IgG, and low-intensity staining for C1q
is seen in only a minority of cases, suggesting that some
C3 deposition is independent of the classical pathway.
The more complex explanation for the postinfectious
GN lesion includes bacterial antigens—circulating
outside the glomerulus as well as planted at the sub-
epithelial and subendothelial spaces of the GBM—
directly activating both the alternative and mannose-
binding lectin complement pathways.33 Thus, the
classical, alternative, and mannose-binding lectin
complement pathways may all be operant to varying
extents in individual patients with postinfectious GN.
The degree to which a complement-focused approach
can transform our thinking about pathogenesis of dis-
ease is perhaps most evident in antineutrophil cyto-
plasmic autoantibody (ANCA)-associated GN. Although
the hallmark ﬁnding on IF staining in ANCA-associated
GN is a paucity of Ig and complement deposition, most
cases have some focal complement deposition at sites of
glomerular injury.34 In ANCA-mediated disease, ANCA
IgG activates cytokine-primed neutrophils that, in turn,
release factors that stimulate activity of the alternative
complement pathway. In mice, administration of anti-
myeloperoxidase IgG leads to a necrotizing, crescentic
GN with neutrophil and macrophage inﬁltration
alongside low-level glomerular IgG and C3 deposition.
In contrast, coadministration of antimyeloperoxidase
IgG with cobra venom factor, which depletes C3, pro-
tects against the development of such a lesion.35 A
similar “resistance” against anti-myeloperoxidase–
mediated GN was shown in knockout mice deﬁcient in
C5 and factor B (both proteins of the alternative
pathway) but not in mice deﬁcient in C4 (an important
protein of both the classical and lectin pathways).35
Therefore, complement targeting therapies (discussed
later in this review) are now being tested as adjunct
treatment in ANCA-associated disease.
Implications for Therapy
A better understanding of the role of complement in
glomerular diseases in turn yields questions about
targeting therapies at the complement pathways.36
The most logical target of therapy for diseases medi-
ated by classical complement pathway activity is the
trigger(s) or inciting event(s) that led to complement
consumption—a documented infection, for example, orKidney International Reports (2016) 1, 148–155
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trigger is not apparent, or in glomerular lesions in
which the lectin or alternative pathways appear to be
playing the dominant role, complement-directed ther-
apies may offer a more precise route of treatment than
traditional use of nonspeciﬁc immunosuppression.
The ﬁrst U.S. Food and Drug Administration–
approved anticomplement therapy is eculizumab, a fully
humanized monoclonal antibody that binds with high
afﬁnity to C5 and prevents the generation of MAC.
Eculizumab was ﬁrst approved for the treatment of
paroxysmal nocturnal hemoglobinuria37 and, more
recently, for treatment of aHUS.38 Both conditions are
thought to be caused by abnormalities in alternative
pathway regulation, usually via a mutation in a com-
plement regulatory protein.A small but growing bodyof
literature has emerged on using eculizumab for C3 glo-
merulopathies.39–44 Only 1 of these reports was from a
prospective trial, the open label study of eculizumab
therapy in 6 subjects with C3 glomerulopathies that was
published in 2 parts, 1 focusing on clinical response to
therapy45 and 1 focusing on the results of biopsies done
before and after treatment.46 All subjects were treated
with eculizumab for 1 year with the same dosing
schedule used for aHUS. After 1 year of therapy, 2 sub-
jects demonstrated signiﬁcantly reduced serum creati-
nine with decreased mesangial and/or endocapillary
proliferation on LM, 1 subject attained remission of
nephrotic syndrome with reduced mesangial prolifera-
tion on LM and partial resorption of deposits on electron
microscopy, and 1 subject had stable laboratory param-
eters but signiﬁcantly reduced mesangial and endoca-
pillary proliferation on LM. The 2 remaining patients,
however, demonstrated steeply declining renal function
during treatment. The remainder of the literature con-
sists of single case reports that are almost entirely posi-
tive,whichmay introduce publication bias.39–41 Overall,
eculizumab’s efﬁcacy in C3 glomerulopathies is still un-
clear and likely will remain unclear until an adequately
powered, appropriately designed trial is performed.
By blocking at C5, eculizumab prevents formation of
C5b, which initiates the formation of the MAC, and
C5a, a potent anaphylatoxin. In theory, the beneﬁts of
eculizumab may result as much from its anti-C5a
effects, which are anti-inﬂammatory, as from its
prevention of MAC formation. A C5aR blocker,
CCX168, is currently being studied as an adjunctive
therapy for ANCA-associated GN on the basis of animal
models clearly implicating a role of alternative pathway
activity in vasculitis pathogenesis. Two randomized
placebo-controlled phase II studies of CCX168 in
ANCA-associated disease, 1 in Europe (NCT01363388)
and 1 in the United States (NCT02222155), have
recently concluded, and blocking speciﬁcally at theKidney International Reports (2016) 1, 148–155level of C5a may have relevance in other glomerular
diseases.
Blockade at the level of C3 may, in theory, be more
effective than anti-C5 therapy given that many abnor-
malities emerge at the level of abnormal C3 convertase
activity of either the alternative (C3bBb) or classic/lectin
pathways (C4b2a). Recently, Zhang et al. reported re-
sults using soluble complement receptor 1 (CR1) in mice
deﬁcient in factor H (a model for C3 GN) and transgenic
for human CR1.47 CR1 is a cell surface protein expressed
on a number of cells, including B cells, some T cells,
dendritic cells, and podocytes, with regulatory activity
at both the level of C3 convertase and C5 convertase.
Additionally, CR1 is the only cofactor of factor I (other
than factor H) that can cleave inactive C3b into smaller
fragments, potentially clearing this breakdown product
of the C3 convertase away from the GBM. Daily
injections of soluble CR1 in factor H– and CR1-deﬁcient
mice led to increases in serum C3 levels and, histo-
pathologically, to decreases in C3 deposition, with
clearance of old C3 deposits demonstrated by reduced
C3c staining. In this same report, Zhang et al. detailed
the short-term use (7 doses) of soluble CR1 in an 8-year-
old girl with end-stage renal disease due to DDD. Serum
C3 levels rose and soluble MAC levels normalized
transiently, although no differences were seen in spec-
imens from biopsies performed before and after treat-
ment. A small phase 1 trial (n ¼ 5) of soluble CR1 (also
called CDX-1135) in pediatric and adult patients with
DDD (NCT01791686), however, was terminated early
after enrolling only a single subject. Other C3-targeting
agents have been evaluated in preclinical settings—
either in animal models of complement-mediated GN or
in vitro—including compstatin analog Cp40,48 recom-
binant forms of complement factor H (CR2-FH and
FH1-5
ˇ
18-20),49,50 and anti-C3 monoclonal antibodies.51
Conclusion
A heightened appreciation of the role of each of the
complement pathways (classical, lectin, and alternative)
in the pathogenesis of glomerular diseases has helped
nephrologists and renal pathologists come closer to
removing the term idiopathic from the lexicon of
glomerular lesions. Moreover, this approach to patho-
genesis inevitably spurs discussions of treatment
directed at the complement system. The advent of
therapies aimed at the complement cascade, now in its
earliest phases, may promise breakthroughs in disease-
speciﬁc treatments that change the natural history of
disease.
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